Premium
Pembrolizumab as first‐line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?
Author(s) -
Goldstein Daniel A.,
Bilal Usama,
Prasad Vinay
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30868
Subject(s) - pembrolizumab , medicine , lung cancer , oncology , censoring (clinical trials) , chemotherapy , intensive care medicine , cancer , immunotherapy , pathology
The KEYNOTE 024 trial compared the safety and efficacy of pembrolizumab versus chemotherapy in the first line setting of PD‐L1 positive metastatic NSCLC and suggested an impressive survival benefit with pembrolizumab. The high level of censoring in the trial casts considerable uncertainty on the actual magnitude of the benefit provided with this treatment.